Nothing Special   »   [go: up one dir, main page]

HK1160776A1 - Methods of treating cancer using il-21 and monoclonal antibody therapy - Google Patents

Methods of treating cancer using il-21 and monoclonal antibody therapy

Info

Publication number
HK1160776A1
HK1160776A1 HK12101199.3A HK12101199A HK1160776A1 HK 1160776 A1 HK1160776 A1 HK 1160776A1 HK 12101199 A HK12101199 A HK 12101199A HK 1160776 A1 HK1160776 A1 HK 1160776A1
Authority
HK
Hong Kong
Prior art keywords
methods
monoclonal antibody
treating cancer
antibody therapy
therapy
Prior art date
Application number
HK12101199.3A
Other languages
English (en)
Inventor
Wayne R Kindsvogel
Steven D Hughes
Richard D Holly
Christopher H Clegg
Donald C Foster
Rebecca A Johnson
Mark D Heipel
Pallavur V Sivakumar
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of HK1160776A1 publication Critical patent/HK1160776A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK12101199.3A 2004-05-20 2012-02-08 Methods of treating cancer using il-21 and monoclonal antibody therapy HK1160776A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57297304P 2004-05-20 2004-05-20
US63538004P 2004-12-10 2004-12-10
US67128105P 2005-04-14 2005-04-14
US68044705P 2005-05-12 2005-05-12

Publications (1)

Publication Number Publication Date
HK1160776A1 true HK1160776A1 (en) 2012-08-17

Family

ID=34971701

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12101199.3A HK1160776A1 (en) 2004-05-20 2012-02-08 Methods of treating cancer using il-21 and monoclonal antibody therapy

Country Status (16)

Country Link
US (8) US20050265966A1 (ja)
EP (4) EP2428216A3 (ja)
JP (2) JP4982373B2 (ja)
KR (1) KR101236177B1 (ja)
CN (2) CN103127502A (ja)
AU (1) AU2005245031B2 (ja)
BR (1) BRPI0511187A (ja)
CA (1) CA2566745A1 (ja)
CY (1) CY1113287T1 (ja)
DK (1) DK1758610T3 (ja)
ES (1) ES2390278T3 (ja)
HK (1) HK1160776A1 (ja)
IL (1) IL179099A (ja)
PL (1) PL1758610T3 (ja)
PT (1) PT1758610E (ja)
WO (1) WO2005113001A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
JP4982373B2 (ja) * 2004-05-20 2012-07-25 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１およびモノクローナル抗体治療を用いる癌を処置する方法
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
CN101553501A (zh) 2006-10-26 2009-10-07 诺沃-诺迪斯克有限公司 Il-21变种
KR100902340B1 (ko) * 2007-08-02 2009-06-12 한국생명공학연구원 Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
US8506933B2 (en) * 2007-11-30 2013-08-13 Msdx, Inc. Methods of detecting a neurological condition via analysis of circulating phagocytes
WO2011019670A1 (en) * 2009-08-10 2011-02-17 Nayak Ramesh C Methods of detecting responses to therapies using perforin levels
CA2781664A1 (en) * 2009-11-27 2011-06-03 Msdx, Inc. Methods of detecting or monitoring activity of an inflammatory or neurodegenerative condition
US8673309B2 (en) 2011-02-11 2014-03-18 Msdx, Inc. Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1
WO2013109904A1 (en) * 2012-01-19 2013-07-25 University Of Miami Compositions, methods and kits for treatment of cancer and autoimmune diseases
WO2013169693A1 (en) * 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
ES2814150T3 (es) 2014-04-08 2021-03-26 Boston Pharmaceuticals Inc Moléculas de unión específicas para IL-21 y usos de las mismas
KR20160120157A (ko) * 2015-04-07 2016-10-17 주식회사 메드팩토 암 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
WO2018067602A1 (en) * 2016-10-03 2018-04-12 Baylor College Of Medicine Modulating cytotoxic cell lytic granule positioning to promote diffuse killing in cellular therapies
CA3075900A1 (en) * 2017-09-15 2019-03-21 Beckman Coulter, Inc. Flow based assays for therapeutics
KR102265437B1 (ko) 2017-11-24 2021-06-15 의료법인 성광의료재단 Nk 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325224B1 (en) 1988-01-22 1996-07-31 ZymoGenetics, Inc. Methods of producing secreted receptor analogs
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
CZ303898B6 (cs) 1998-08-11 2013-06-19 Biogen Idec Inc. Rituximab jako lécivo pro udrzovací terapii
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
EP1189931B1 (en) * 1999-07-02 2006-06-21 Genentech, Inc. Peptide compounds that bind her2
IT1311703B1 (it) 1999-07-23 2002-03-19 Sipa Spa Impianto ad alta efficienza di soffiaggio di preforme
WO2001077171A2 (en) 2000-04-05 2001-10-18 Zymogenetics, Inc. Soluble zalpha11 cytokine receptors
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
AU2002362098A1 (en) 2001-12-07 2003-06-23 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
CN101914158A (zh) * 2002-02-14 2010-12-15 免疫医疗公司 抗cd 20抗体及其融合蛋白和使用方法
SI1503794T1 (sl) * 2002-04-12 2012-09-28 Medarex Inc Postopek zdravljenja z uporabo ctla-4 antiteles
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
ES2381265T3 (es) * 2002-06-07 2012-05-24 Zymogenetics, Inc. Uso de IL-21 y anticuerpo monoclonal para tratar cánceres sólidos
WO2004032857A2 (en) * 2002-10-08 2004-04-22 Immunomedics, Inc. Antibody therapy
US20070092485A1 (en) * 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
ES2334127T3 (es) * 2002-12-13 2010-03-05 Zymogenetics, Inc. Produccion de il-21 en huespedes procariotas.
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
CA2542662A1 (en) * 2003-10-17 2005-04-28 Novo Nordisk A/S Pharmaceutical combinations comprising il-21
JP4982373B2 (ja) * 2004-05-20 2012-07-25 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１およびモノクローナル抗体治療を用いる癌を処置する方法
PL1814580T3 (pl) * 2004-11-24 2017-03-31 Fred Hutchinson Cancer Research Center Metody stosowania il-21 do adoptywnej immunoterapii i identyfikacji antygenów guza

Also Published As

Publication number Publication date
EP2431050A8 (en) 2012-09-26
US20090087404A1 (en) 2009-04-02
EP1758610A1 (en) 2007-03-07
US20050265966A1 (en) 2005-12-01
US20110300098A1 (en) 2011-12-08
US20070178063A1 (en) 2007-08-02
IL179099A (en) 2011-03-31
CN102188704B (zh) 2013-04-24
WO2005113001A1 (en) 2005-12-01
KR101236177B1 (ko) 2013-02-22
IL179099A0 (en) 2007-03-08
EP2428216A3 (en) 2012-05-23
JP2007538108A (ja) 2007-12-27
EP2428216A2 (en) 2012-03-14
US20090269304A1 (en) 2009-10-29
CA2566745A1 (en) 2005-12-01
EP2425847A1 (en) 2012-03-07
US20070048264A1 (en) 2007-03-01
DK1758610T3 (da) 2012-10-15
AU2005245031A1 (en) 2005-12-01
BRPI0511187A (pt) 2007-12-04
US20070122382A1 (en) 2007-05-31
US20110086004A1 (en) 2011-04-14
CN102188704A (zh) 2011-09-21
PL1758610T3 (pl) 2012-11-30
ES2390278T3 (es) 2012-11-08
EP1758610B1 (en) 2012-07-04
KR20070026588A (ko) 2007-03-08
CN103127502A (zh) 2013-06-05
JP4982373B2 (ja) 2012-07-25
CY1113287T1 (el) 2016-04-13
AU2005245031B2 (en) 2011-08-18
EP2431050A1 (en) 2012-03-21
JP2012102122A (ja) 2012-05-31
EP2428216A9 (en) 2012-04-25
PT1758610E (pt) 2012-10-01

Similar Documents

Publication Publication Date Title
HK1160776A1 (en) Methods of treating cancer using il-21 and monoclonal antibody therapy
IL179095A0 (en) Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna
HRP20181565T1 (hr) Monoklonska protutijela protiv klaudina-18 za liječenje karcinoma
HK1204476A1 (en) Compounds and methods for treatment of cancer
AU2006226897B2 (en) Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors
IL179515A0 (en) Method of administering and using vegf inhibitors for the treatment of human cancer
HK1081448A1 (en) Bispecific anti-erb-b antibodies and their use in tumor therapy
IL186659A0 (en) Il-31 monoclonal antibodies and methods of use
HK1099935A1 (en) Anti-cd3 antibodies and methods of use thereof -cd3
EP1811844A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP1793858A4 (en) HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT
IL173477A0 (en) Bispecific antibodies for inducing apoptosis of tumor and diseased cells
IL188588A0 (en) Anti-ctla -4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
EP1976554A4 (en) S-N-ACETYL SIALIC ACID ANTIGENS, ANTIBODIES THEREOF AND METHODS OF USE THEREOF IN ANTICANCER THERAPIES
IL177104A (en) Ccx-ckr2 binding agents for treatment of cancer and arthritis and for wound healing
EP1583536A4 (en) METHOD OF TREATING PROSTATIC CANCER AND COMPOSITION FOR TREATMENT THEREOF
HK1155670A1 (en) Therapeutic use of anti-cs1 antibodies
EP1789027A4 (en) Therapeutic Use of Anti- TF Antigen Antibodies
SI1758610T1 (sl) Postopek za tretiranje raka z uporabo il in terapije z monoklonalnimi protitelesi
WO2009149306A9 (en) Complement depleting compounds and methods of treating cancer comprising monoclonal antibody therapy and said complement depleting compounds
IL172533A0 (en) Humanized anti-ccr2 antibodies and methods of use
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
EP1817062A4 (en) RADIATION DOSIMETRY AND BLOCKING ANTIBODY AND METHOD AND USE THEREOF IN CANCER TREATMENT
IL165752A0 (en) Monoclonal antibody PAM4 and its use for diagnosisand therapy of pancreatic cancer
IL164683A0 (en) Method of general cancer therapy by in situ production of f5 antibodies

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170520